IP Library Granted Patent US 9,498,442
Granted Patent B2
US 9,498,442 · App. 14/261,337 · Granted Nov 22, 2016

Rifaximin powder, process for preparing the same an controlled release compositions containing said rifaximin useful for obtaining a long-lasting effect

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,498,442
App. No.
14/261,337
Granted
Nov 22, 2016
Kind
B2
Abstract

The present invention describes rifaximin powder and to a process for preparing the same. The invention relates also to a pharmaceutical composition in solid form comprising said rifaximin, pharmaceutically acceptable excipients and optionally other ingredients. The compositions according to the invention are suitable for oral administration and are characterized by producing a controlled release of rifaximin, whereby a long-lasting effect is obtained in a patient.

Claims (9)

1. A method for producing rifaximin in amorphous form characterized by an X-Ray diffraction spectrum showing diffraction halo peaks in the range 7.75°±0.2-18.33°±0.2, 2θ, with maximum at about 7.75°±0.2 and in the range 14.54°±0.2 and 18.33°±0.2, 2θ, said method comprising:

subjecting a rifaximin solution to a spray-drying treatment in an atomizer by using a nozzle flow with a heated gas at a pressure comprised between 1.0 and 1.5 bar.

2. The method according to claim 1 , wherein said rifaximin solution contains an organic solvent.

3. The method according to claim 1 , wherein said rifaximin solution comprises an amount of organic solvent comprised between 1 and 40 liters per kg of rifaximin.

4. The method according to claim 1 , wherein said gas is air.

5. The method according to claim 1 , wherein the produced rifaximin is dried until reaching a constant weight at a temperature between 20° C. and 120° C.

6. The method according to claim 1 , wherein the X-Ray diffraction spectrum of the produced rifaximin does not show any peaks characterizing the crystallinity.

7. A method for producing rifaximin in amorphous form characterized by an X-Ray diffraction spectrum showing diffraction halo peaks in the range 7.75°±0.2-18.33°±0.2, 2θ, with maximum at about 7.75°±0.2 and in the range 14.54°±0.2 and 18.33°±0.2, 2θ, said method comprising:

subjecting a rifaximin solution to a spray-drying treatment in an atomizer by using a nozzle flow with a heated gas at a pressure comprised between 0.5 and 2.5 bar.

Assignments (3)
CHANGE OF ADDRESS Recorded Oct 15, 2019
From: ALFASIGMA S.P.A.
To: ALFASIGMA S.P.A.
Reel/Frame 050727/0652 →
MERGER Recorded Nov 14, 2017
From: ALFA WASSERMANN S.P.A.
To: ALFASIGMA S.P.A.
Reel/Frame 045061/0645 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2015
From: VISCOMI, GIUSEPPE CLAUDIO; MAFFEI, PAOLA; LAURO, VITTORIA; BARBANTI, MIRIAM; CONFORTINI, DONATELLA; BRAGA, DARIO
To: ALFA WASSERMANN S.P.A.
Reel/Frame 035408/0500 →